| 张军丽.埃克替尼对EGFR基因突变型非小细胞肺癌患者治疗效果分析[J].安徽医药,2018,22(9):1807-1809. |
| 埃克替尼对EGFR基因突变型非小细胞肺癌患者治疗效果分析 |
| Analysis on the therapeutic effect of Icotinib on patients with EGFR mutated non-small cell lung cancer |
| 投稿时间：2017-03-09 |
| DOI： |
| 中文关键词: 埃克替尼 EGFR基因突变 非小细胞肺癌 疗效 |
| 英文关键词: Icotinib EGFR gene mutation Non-small cell lung cancer Curative effect |
| 基金项目: |
|
| 摘要点击次数: 1992 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的 探讨埃克替尼对EGFR基因突变型非小细胞肺癌患者治疗效果及安全性。方法 择取确诊为非小细胞肺癌(NSCLC)患者60例的病例资料进行回顾性分析,经EGFR检测均为EGFR基因突变型,其中外显子19缺失患者20例(19缺失组),外显子21L858R突变患者24例(21突变组),外显子20T790M突变患者16例(20突变组)。三组均给予盐酸埃克替尼治疗,评价其治疗效果及安全性。结果 20突变组部分缓解、疾病稳定例数均不及19缺失组、21突变组(均P<0.05)；20突变组近期有效率为6.25%,疾病控制率为25.00%,中位无进展生存期为1.8个月,中位总生存期为12.5个月,效果均不及19缺失组和21突变组(P<0.05)；三组中最常见的不良反应为皮疹、腹泻、恶心、腹胀,各组大多均为不良反应Ⅰ级和Ⅱ级,各组间不良反应发生率比较,差异无统计学意义(P>0.05)。结论 盐酸埃克替尼用于EGFR基因突变型NSCLC患者的治疗,对外显子19缺失、21L858R突变患者的治疗效果较好,且较安全。 |
| 英文摘要: |
| Objective Investigate the effects and safety of Icotinib on patients with EGFR mutated non-small cell lung cancer (NSCLC).Methods 60 cases of NSCLC patients were selected and retrospectively analyzed.EGFR gene mutation was detected.There were 19 cases of exon deletion in the treatment group (n=20,9 deletion group),Exon 21L858R mutation was found in 24 patients (Group 21),Exon 20T790M mutation was found in 16 patients (Group 20),the three groups were given Icotinib treatment to evaluate the efficacy and safety of the treatment.Results In the 20 mutation group,the number of PR,SD cases in the mutation group was less than that in the 19 deletion group and the 21 mutation group,P<0.05;20 in the mutation group,the short-term effective rate was 6.25%,the disease control rate was 25.00%.The median progression free survival was 1.8 months and the median overall survival was about 12.5 months,which were less than 19 deletion group and the 21 mutation group,P<0.05.The most common adverse events in the three groups were rash,diarrhea,nausea,abdominal distension.The most adverse reactions wereⅠrank and Ⅱ rank.The incidence of adverse reactions in each group was compared,there was no statistical significance (P>0.05).Conclusion Icotinib hydrochloride is used in the treatment of EGFR gene mutations in patients with NSCLC.The treatment effect of exon 19 deletion and 21L858R mutation is better and safer. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
